E

    Edgewise Therapeutics Inc (EWTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $41.77
    -0.99 (-2.32%)

    Market Cap: $4.64B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    +0.09%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$2.81
    Range$-0.64 - $11.45
    10 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.52-118.5%
    60d ago$1.13-59.6%
    30d ago$1.13-59.6%
    7d ago$2.81+0.1%
    Current$2.81
    Revenue Consensus
    $129M
    Range$0 - $1.6B
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.47
    Range$-4.27 - $8.43
    10 analysts
    Revenue Consensus
    $10M
    Range$-129166670 - $1.5B
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.47---
    Sep 26EST
    		-$2.81---
    Jun 26
    		$-0.53$-0.48-10.42%Miss-55.9%
    Mar 26
    		$-0.46$-0.48+4.17%Beat-7.0%
    Dec 25
    		$-0.47$-0.43-9.30%Miss-11.9%
    Sep 25
    		$-0.39$-0.40+2.50%Beat-8.3%
    Jun 25
    		$-0.34$-0.42+19.05%Beat+0.0%
    Mar 25
    		$-0.43$-0.42-2.38%Miss-30.3%
    Dec 24
    		$-0.42$-0.42+0.52%Beat+10.6%
    Sep 24
    		$-0.36$-0.37+2.70%Beat+12.2%
    Jun 24
    		$-0.34$-0.34+0.00%Beat+0.0%
    Mar 24
    		$-0.33$-0.41+19.51%Beat+8.3%
    Dec 23
    		$-0.47$-0.43-9.30%Miss-51.6%
    Sep 23
    		$-0.41$-0.40-2.50%Miss-20.6%
    Jun 23
    		$-0.34$-0.40+15.00%Beat-6.3%
    Mar 23
    		$-0.36$-0.35-2.86%Miss-20.0%
    Dec 22
    		$-0.31$-0.33+6.06%Beat-19.2%
    Sep 22
    		$-0.34$-0.36+5.56%Beat-30.8%
    Jun 22
    		$-0.32$-0.32+0.00%Beat-52.4%
    Mar 22
    		$-0.30$-0.28-7.14%Miss-114.3%
    Dec 21
    		$-0.26$-0.25-4.00%Miss-
    Sep 21
    		$-0.26$-0.24-8.33%Miss-
    Jun 21
    		$-0.21$-0.17-23.53%Miss-
    Mar 21
    		$-0.14$-0.15+6.67%Beat-
    Dec 20
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-22.58EV/EBITDA-2.60x
    Price/FCF-28.31xFCF Yield-3.53%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-38.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio16.24xQuick Ratio16.24x
    Trading Statistics
    Beta0.33Avg Volume1.35M
    52-Week High$48.4052-Week Low$13.69

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$44.01
    SMA 20$44.08
    SMA 50$42.04
    SMA 200$32.57
    EMA 10$43.53
    EMA 20$43.32
    EMA 50$41.50
    EMA 200$33.59

    MACD

    Line: 0.53Signal: 0.90Hist: -0.37

    ADX

    ADX: 12.3+DI: 19.9-DI: 25.9

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down20.0
    PSAR$46.59

    Bollinger Bands

    Upper Band$45.96
    Lower Band$42.19
    %B Position855%(Upper)
    Band Width-0.11

    RSI (14-Day)

    Neutral
    45.7

    Momentum Oscillators

    Stoch %K28.0
    Stoch %D38.9
    Williams %R-81.0
    ROC (10d)-5.2%
    Momentum-2.27
    CCI (20d)-279.6
    MFI (14d)55.3

    Volatility Measures

    ATR (14d)$2.22(5.3%)
    StdDev (20d)0.94
    Hist Vol71.4%(High)

    Volume Flow

    VWAP$41.62
    OBV-13.7M
    AD Line24.9M
    CMF (20d)0.169

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.8x
    VWMA (20d)$44.30

    Pivot Points

    R3$45.20
    R2$44.69
    R1$43.73
    Pivot Point$43.22
    S1$42.26
    S2$41.75
    S3$40.79

    Advanced Oscillators

    TSI6.70
    Ultimate Osc51.1
    KST67.80

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2.12M$0$0$0$2.25M$0
    Cost of Revenue$0$0N/A$0$0$0$1.06M$0$0$0$533,000$0
    Gross Profit$0$0N/A$0$0$0$1.06M$0$0$0$1.72M$0
    Operating Expenses$61.94M$54.12M$55.98M$46.86M$42.61M$45.96M$45.54M$40.43M$38.11M$34.75M$33.86M$29.45M
    R&D$47.55M$42.65M$43.59M$37.48M$33.56M$36.76M$36.37M$32.22M$30.68M$27.69M$27.68M$23.79M
    SG&A$14.39M$11.46M$12.38M$9.38M$9.05M$9.20M$9.17M$8.21M$7.43M$7.06M$6.18M$5.67M
    Operating Income$-61,943,000$-54,115,000$-55,979,000$-46,858,000$-42,610,000$-45,959,000$-45,540,000$-40,432,000$-38,107,000$-34,753,000$-33,862,000$-29,452,000
    Interest Income$4.62M$5.10M$5.76M$6.19M$6.50M$5.16M$5.88M$6.30M$6.61M$6.23M$3.72M$3.74M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-57,327,000$-49,013,000$-50,216,000$-40,666,000$-36,115,000$-40,798,000$-39,662,000$-34,129,000$-31,497,000$-28,525,000$-30,143,000$-25,713,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-57,327,000$-49,013,000$-50,216,000$-40,666,000$-36,115,000$-40,798,000$-39,662,000$-34,129,000$-31,497,000$-28,525,000$-30,143,000$-25,713,000
    EBITDA$-62,155,000$-54,538,000$-56,887,000$-48,344,000$-44,246,000$-47,328,000$-47,513,000$-43,070,000$-41,126,000$-37,378,000$-35,501,000$-31,330,000
    EBIT$-61,943,000$-54,115,000$-55,979,000$-46,858,000$-42,610,000$-45,959,000$-45,540,000$-40,432,000$-38,107,000$-34,753,000$-33,862,000$-29,452,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EWTX

    News

    Edgewise Therapeutics presents positive Phase 2 trial data for EDG-7500 in hypertrophic cardiomyopathy at ESC Congress

    Edgewise Therapeutics announced positive top-line results from its 12-week Phase 2 CIRRUS-HCM trial for EDG-7500, a new oral drug for hypertrophic cardiomyopathy (HCM). The data, to be presented at the European Society of Cardiology Congress in August 2026, suggest EDG-7500 could improve heart relaxation and function in symptomatic HCM patients. This trial is part of a broader study addressing the unmet need in treating this genetic heart disease.

    Pluang•8/24/26•
    Bullish

    Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

    Edgewise Therapeutics announced that its CIRRUS-HCM abstract has been selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress in August 2026. The presentation will highlight positive top-line data from the 12-week Phase 2 CIRRUS-HCM trial, evaluating EDG-7500, a novel cardiac sarcomere modulator, for the safety and efficacy in treating obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). HCM is a common genetic heart disease causing significant functional limitations and is associated with heart failure, abnormal heart rhythms, and sudden cardiac death.

    PR Newswire•8/24/26•
    Bullish

    Edgewise's 12-week heart treatment study gets a late-breaking slot in Munich

    Edgewise Therapeutics announced that its CIRRUS-HCM Phase 2 trial data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, has been selected for a late-breaking science presentation at the ESC Congress 2026 in Munich. The presentation will feature 12-week top-line data from the trial, focusing on both obstructive and nonobstructive forms of the condition. This announcement highlights the company's focus on cardiovascular diseases and the potential of EDG-7500 as a novel therapeutic approach.

    Stock Titan•8/24/26•
    Somewhat-Bullish

    JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock

    JPMorgan Chase & Co. has increased its price target for Edgewise Therapeutics (NASDAQ:EWTX) to $60 from $53, maintaining an "overweight" rating and suggesting a 37.61% upside. Despite this positive analyst sentiment and a "Moderate Buy" consensus rating, the company recently missed quarterly EPS estimates, and insiders have sold a significant number of shares. Hedge funds, however, have either increased or initiated new positions in the stock.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?

    Edgewise Therapeutics (EWTX) reported wider net losses in Q2 2026 and the first half of 2026, highlighting increased spending relative to its revenue base. Despite this, the stock rose 6.6%, suggesting investors are focused on future clinical and regulatory catalysts for its late-stage pipeline. The widening losses emphasize the company's reliance on external capital and the importance of future funding rounds.

    Simply Wall Street•8/20/26•
    Somewhat-Bearish

    Frequently Asked Questions About EWTX

    Does EWTX pay dividends?
    Edgewise Therapeutics Inc (EWTX) does not currently pay a regular dividend.
    What is EWTX's market cap?
    Edgewise Therapeutics Inc (EWTX) has a market capitalization of $4.64B with a current stock price of $41.77.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In